Head and Neck Squamous Cell Carcinoma – Global Drug Forecast and Market Analysis to 2030
All the vital news, analysis, and commentary curated by our industry experts.
Head and Neck Squamous Cell Carcinomas Market Report Overview
Head and neck squamous cell carcinoma (HNSCC) was the sixth most common cancer type by worldwide incidence in 2020. However, until recently, there had been limited research and development in HNSCC, resulting in a market with little competition and a stagnant pipeline. Historically, cytotoxic chemotherapies have made up the majority of the HNSCC market. There is currently little competition between targeted therapies in the HNSCC market, leaving an area of considerable opportunity for interested newcomers. Despite the approvals of PD-1 inhibitors, which have changed the treatment for platinum (Pt)-refractory HNSCC patients, cisplatin-based chemotherapy still remains the standard treatment for locally advanced (LA) HNSCC and newly diagnosed recurrent/metastatic (R/M) HNSCC.
The approval of Eli Lilly’s Erbitux in 2006 introduced the only non-chemotherapy agent available to HNC patients until 2016. In 2016, immunotherapies entered the HNSCC space with the approval of Merck & Co.’s Keytruda and BMS’ Opdivo as treatments for R/M HNSCC, followed by Keytruda’s expansion into first-line setting for PD-L1 positive and all-comer patients. During 2020-2030, the competitive landscape will continue to evolve with the label extension of Keytruda as an adjuvant treatment for LA-HNC patients, and the launch of 11 pipeline agents. Among these, six belong to the ICI class, which, as a class, are expected to be the main driver of market growth. As a result of this active level of clinical development, specifically with immunotherapies, the HNSCC market is expected to grow dramatically across the 8MM.
This report covers opportunities for various marketed agents and pipeline agents in development across the 8MM, clinical and commercial assessments for agents in late-stage clinical development, R&D strategies, and innovative approaches in development for HNSCC breast cancer. This edition provides an update to the previous sales forecast for marketed and pipeline agents and highlights expected market dynamics by country and class of therapy across the forecast period, 2020-2030.
KEY QUESTIONS ANSWERED
– 11 late-stage pipeline agents are going to enter the HNSCC market from 2021 onwards. What impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
– What are the current unmet needs in HNSCC, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
– What is the market outlook in the 8MM from 2020-2030? Considering major patent expiries, launch of new premium priced agents and expected label expansions.
– What are the main corporate trends? Who are the current and future players?
Overview of HNSCC including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
Topline HNSCC market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting HNSCC therapeutics sales in the 8MM.
Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase III).
Analysis of the current and future market competition in the global HNSCC market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
The main drivers of growth include the anticipated label expansion of currently marketed therapies and the approval and launch of 11 pipeline therapies and greater market access across the 8MM for premium priced agents.
The main barriers to growth in the 8MM are the patent expiries of the leading brands across the 8MM.
The most important unmet needs in the HNSCC market include: Efficacious treatments for patients via personalization of therapy and identification of druggable targets.
Reasons to Buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
Develop business strategies by understanding the trends shaping and driving the global HNSCC therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HNSCC market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the global HNSCC therapeutics market from 2020-2030.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Iovance Biotherapeutics Inc
Table of Contents
Table of Contents
| About GlobalData
1 Head and Neck Squamous Cell Carcinoma: Executive Summary
1.1 The Head and Neck Squamous Cell Carcinoma Market Will Grow to $5.2B in 2030
1.2 Merck & Co. Expected to Maintain Its Market-Leading Position
1.3 Extending Overall Survival Remains a Major Unmet Need
1.4 Immune Checkpoint Inhibitors Expected to Launch in Locally Advanced and Recurrent/Metastatic Settings
1.5 What Do Physicians Think?
2.2 Related Reports
2.3 Upcoming Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.2 Classification or Staging Systems
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 8MM Forecast Methodology
4.4.2 Forecast Assumptions and Methods
4.4.3 Forecast Assumptions and Methods: Diagnosed Incident Cases of HNC
4.4.4 Forecast Assumptions and Methods: Diagnosed Incident Cases of HNC by Histology Distribution
4.4.5 Forecast Assumptions and Methods: Diagnosed Incident Cases of HNC by Clinical Stage at Diagnosis for Squamous Cell Carcinoma
4.4.6 Forecast Assumptions and Methods: Diagnosed Incident Cases of Oropharynx Cancer by Risk Factor (HPV+ and HPV-)
4.4.7 Forecast Assumptions and Methods: Diagnosed Incident Cases of Nasopharynx Cancer by Risk Factor (EBV+)
4.4.8 Forecast Assumptions and Methods: Tobacco Smoking History
4.4.9 Forecast Assumptions and Methods: Five-Year Diagnosed Prevalent Cases of HNC
4.5 Epidemiological Forecast for HNC (2020-2030)
4.5.1 Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer (ICD-10 = C00-C06, C09, C12-C14, C32, and C10 [HPV-])
4.5.2 Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer (ICD-10 = C00-C06, C09, C12-C14, C32, and C10 [HPV-]) by Risk Factor, Histology Distribution, and Stage at Diagnosis
4.5.3 Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer (ICD-10 = C00-C06, C09, C12-C14, C32, and C10 [HPV-])
4.5.4 Diagnosed Incident Cases of Oropharynx Cancer (ICD-10 = C10)
4.5.5 Diagnosed Incident Cases of Oropharynx Cancer by Risk Factors, Histology Distribution, and Stage at Diagnosis
4.5.6 Diagnosed Incident Cases of Nasopharynx Cancer (ICD-10 = C11)
4.5.7 Age-Specific Diagnosed Incident Cases of Nasopharynx Cancer
4.5.8 Sex-Specific Diagnosed Incident Cases of Nasopharynx Cancer
4.5.9 Diagnosed Incident Cases of Nasopharynx Cancer by Risk Factors, Histology Distribution, and Stage at Diagnosis
4.5.10 Five-Year Diagnosed Prevalent Cases of Nasopharynx Cancer
4.5.11 Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer (ICD-10 = C07-C08 and C30-C31)
4.5.12 Age-Specific Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer
4.5.13 Sex-Specific Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer
4.5.14 Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Risk Factors, Histology Distribution, and Stage at Diagnosis
4.5.15 Five-Year Diagnosed Prevalent Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer
4.6.1 Epidemiological Forecast Insight
4.6.2 COVID-19 Impact
4.6.3 Limitations of the Analysis
4.6.4 Strengths of the Analysis
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.2 Key Opinion Leader Insights on Disease Management
6 Current Treatment Options
7 Unmet Needs and Opportunity Assessment
7.2 Superior Efficacy/Overall Survival
7.3 Reducing Risk of Recurrence
7.4 Personalized Therapy in LA-HNSCC
7.5 Identification of New Druggable Targets
7.6 Therapeutic De-Intensification in HPV-Positive Oropharyngeal HNSCC Patients
8 R&D Strategies
8.1.1 Immunotherapy in Locally Advanced HNSCC
8.1.2 Precision Medicine in Head and Neck Cancer
8.1.3 Regulatory Submissions Through Overseas Clinical Trials
8.2 Clinical Trials Design
8.2.1 Preferred Trial Endpoints
8.2.2 Study Inclusion/Exclusion Criteria
8.2.3 Need for Head-to-Head Comparisons
9 Pipeline Assessment
9.2 Promising Drugs in Clinical Development
10 Pipeline Valuation Analysis
10.2 Competitive Assessment
11 Current and Future Players
11.2 Deal-Making Trends
12 Market Outlook
12.1 Global Markets
12.1.2 Drivers and Barriers – Global Issues
12.2.2 Key Events
12.2.3 Drivers and Barriers
12.3.2 Key Events
12.3.3 Drivers and Barriers
12.4.2 Key Events
12.4.3 Drivers and Barriers
12.5 Urban China
12.5.2 Key Events
12.5.3 Drivers and Barriers
13.3.1 Forecasting Methodology
13.4 Primary Research – Key Opinion Leaders Interviewed for This Report
13.5 Primary Research – Prescriber Survey
13.6 About the Authors
13.6.2 Therapy Area Director
13.6.5 Global Director of Therapy Analysis and Epidemiology
13.6.6 Global Head and EVP of Healthcare Operations and Strategy
| Contact Us
Frequently asked questions
Undecided about purchasing this report?Enquire Before Buying
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Business Intelligence & Marketing Manager, SAL Heavy Lift
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
Market Analyst & Management, Liebherr-Werk
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Head of Key Accounts, Saab AB
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Marketing Intelligence Manager, Portugal Foods
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Head of Customer Insight and Research, Standard Chartered
Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.
I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.
I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.
Head of Consumer Sensory Insights, Givaudan
“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.
Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”
Senior Account Manager, TSYS
GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.
I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.
One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.